PMID-36015082 – Difelikefalin CKD-Associated Pruritus Systematic Review
Topf J, Engel B, Engel S, et al. "Difelikefalin in the Treatment of Chronic Kidney Disease-Associated Pruritus: A Systematic Review," Dermatol Ther (Heidelb), 2022;12(9):2025-2046.
Quick Reference
| Property | Value |
|---|---|
| PMID | 36015082 |
| DOI | 10.1007/s13555-022-00782-y |
| Year | 2022 |
| Journal | Dermatology and Therapy |
| Study Type | Systematic Review |
| Evidence Level | I |
| Sample | Multiple RCTs and open-label studies pooled |
| Peptide(s) Studied | Difelikefalin |
Key Findings
- Comprehensive review of all clinical evidence for difelikefalin in CKD-associated pruritus (CKD-aP)
- Confirmed significant itch reduction across Phase II and Phase III trials (KALM-1, KALM-2)
- Long-term open-label data (up to 52 weeks) showed sustained antipruritic efficacy
- Peripheral kappa-opioid receptor (KOR) agonism represents a novel mechanism distinct from traditional antipruritics
- Safety profile favorable: no CNS opioid effects, no abuse potential, no respiratory depression
- Difelikefalin does NOT cross the blood-brain barrier due to D-amino acid incorporation and hydrophilic design
- Identified ongoing development of oral formulation for non-dialysis CKD-aP
Study Design
Systematic review following PRISMA guidelines. Searched PubMed, Embase, and ClinicalTrials.gov for all clinical studies of difelikefalin in CKD-aP. Included Phase I-III RCTs and open-label studies. Assessed efficacy (WI-NRS, 5-D Itch, Skindex-10) and safety outcomes.
Limitations
- Limited to CKD-associated pruritus; other pruritic conditions not covered
- Most data from IV formulation in hemodialysis patients
- Industry-sponsored trials
- No head-to-head comparisons with other antipruritic agents
- Publication bias possible
Clinical Relevance
This systematic review synthesizes the complete clinical evidence base for difelikefalin, establishing it as the first targeted therapy for CKD-aP. The review highlights the unmet need (40-70% of HD patients affected, no prior FDA-approved therapy) and positions difelikefalin as a landmark in both nephrology and peptide therapeutics. The pharmacological principle of peripheral KOR agonism without BBB penetration is a design innovation relevant to future peptide drug development. The oral formulation in development could expand the addressable population to non-dialysis CKD patients.
Related
#research #systematic-review #evidence-level-I #difelikefalin #fda-approved